Long-acting antiviral agents for HIV treatment.
Journal Information
Full Title: Curr Opin HIV AIDS
Abbreviation: Curr Opin HIV AIDS
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Acquired Immunodeficiency Syndrome
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Conflicts of interest D.M. is an employee of and owns stock in GlaxoSmithKline. GlaxoSmithKline has a majority shareholding in ViiV Healthcare, which is developing cabotegravir for HIV treatment. M.B. has acted as an advisor and has received speaking fees and travel and research grants from ViiV Healthcare, Janssen, Merck Sharp & Dohme, Bristol-Myers Squibb, and Gilead Sciences. The authors have no conflicts of interest."
"Financial support and sponsorship No financial support was provided for the drafting of this manuscript."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025